BACKGROUND: The natural course of idiopathic @entity8 ( @entity8 ) varies, as it is known through favorable outcomes in most @entity1 . However, one third of @entity1 with idiopathic @entity8 will slowly progress to @entity454 ( @entity454 ). To prevent disease progression, @entity1 at high risk to develop @entity454 are treated with immunosuppressive agents. Therefore, a correct selection of @entity1 who need immunosuppressive treatment is important. METHODS: Here, we evaluated the prognostic value of anti- @entity8164 antibody (anti- @entity8164 ) levels regarding clinical outcome in a well-defined cohort of 73 @entity8164 -related @entity8 @entity1 with long-term follow-up. At baseline, @entity1 were subdivided into @entity1 with either low or high antibody levels based on ELISA testing. RESULTS: Spontaneous remission rates were highest among @entity1 with low anti- @entity8164 levels (79%; hazard ratio 2.72 (95% CI 1.22-6.08), p = 0.02) after a median follow-up of 2.9 (95% CI 0.8-5.0, p < 0.001) years, whereas high anti- @entity8164 levels were associated with persistent @entity644 (p = 0.04) and/or the need for immunosuppressive therapy (p < 0.001). Renal survival rates were 97% at 5 years, 93% at 10 years, and 89% at 15 years; however, this was not different between the anti- @entity8164 groups. @entity454 occurred significantly faster in @entity1 with severe @entity644 as compared to @entity1 with either mild (p = 0.02) or moderate @entity644 (p = 0.05). CONCLUSIONS: Low anti- @entity8164 levels may predict spontaneous remissions in @entity1 with @entity8164 -related @entity8 . Therefore, we suggest that quantification of anti- @entity8164 is of value to monitor these @entity1 .

Anti- @entity8164 Antibodies as a Prognostic Factor in XXXX -Related @entity8 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['membranous nephropathy', 'MN'] @entity8164 :: ('22925', 'Gene') :: ['phospholipase A2 receptor 1', 'PLA2R'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']
@entity8164 :: (22925,Gene) :: ['PLA2R']
